Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant salvage antiemetic treatment for CINV in gastrointestinal cancer patients receiving moderately emetogenic chemotherapy
ChiCTR-OIC-17012883Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by West China Hospital of Sichuan University. Primary endpoint: Response rate of chemotherapy-induced nausea and vomiting. Started Oct 2017; status: recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR-OIC-17012883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012883.